KYTHERA Biopharmaceuticals (NASDAQ:KYTH) CFO John Smither unloaded 40,000 shares of the stock in a transaction dated Tuesday, September 10th. The stock was sold at an average price of $30.02, for a total transaction of $1,200,800.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.
A number of research firms have recently commented on KYTH. Analysts at Cowen and Company initiated coverage on shares of KYTHERA Biopharmaceuticals (NASDAQ:KYTH) in a research note to investors on Friday. They set an “outperform” rating and a $50.00 price target on the stock. Separately, analysts at Leerink Swann raised their price target on shares of KYTHERA Biopharmaceuticals (NASDAQ:KYTH) from $28.00 to $34.00 in a research note to investors on Wednesday, August 7th. Finally, analysts at JPMorgan Chase & Co. raised their price target on shares of KYTHERA Biopharmaceuticals (NASDAQ:KYTH) from $30.00 to $34.00 in a research note to investors on Wednesday, August 7th.
Two research analysts have rated the stock with a hold rating and two have issued a buy rating to the company. The company currently has an average rating of “Buy” and an average price target of $34.60.
Shares of KYTHERA Biopharmaceuticals (NASDAQ:KYTH) traded up 2.34% on Tuesday, hitting $32.74. 210,405 shares of the company’s stock traded hands. KYTHERA Biopharmaceuticals has a one year low of $14.07 and a one year high of $32.00. The stock’s 50-day moving average is $26.51 and its 200-day moving average is $24.55. The company’s market cap is $610.3 million.
KYTHERA Biopharmaceuticals (NASDAQ:KYTH) last posted its quarterly earnings results on Tuesday, August 6th. The company reported ($0.67) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.70) by $0.03. On average, analysts predict that KYTHERA Biopharmaceuticals will post $-2.97 earnings per share for the current fiscal year.
KYTHERA Biopharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of prescription products for the aesthetic medicine market.